Testimonials about LPBI
2023
UPDATED on 5/24/2023
LPBI Group’s Founder was interviewed by Montero Language Services for their Testimonial on the Translation JOINT Project that yielded the BioMed e-Series Spanish-language Edition on Amazon.com
https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/
POST 23/5 – TESTIMONIO
AVIVA LEV-ARI, PhD, RN
“A miracle that came true”. This is how Aviva Lev-Ari, PhD, RN founder of LPBI Group’s described what she and her venture had accomplished by partnering with Montero for a “monumental” #Medicine and #LifeSciences translation project. It was “monumental” because it involved 18 books in medicine 😊.
Dr. Lev-Ari is the editor-in-chief behind the Medicine and Life Sciences Scientific Journal, PharmaceuticalIntelligence.com An open access scientific journal that has over 2.2 million views by over 1.4 million visitors. Over 6,170 scientific articles and over 740 categories of research in its ontology.
Between June 2013 and February 2021, LPBI Group’s team published eighteen 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗻𝗶𝗰 medical 𝗯𝗼𝗼𝗸𝘀 covering five medical specialties:
- Series A: Cardiovascular Diseases – Six volumes
- Series B: Frontiers in Genomics – Two volumes
- Series C: Cancer & Oncology – Two volumes
- Series D: Immunology – Four volumes [volume 2&3 published in one book]
- Series E: Patient-Centered Medicine & Precision Medicine – Four volumes
These e-books, including 𝟮,𝟳𝟮𝟴 scientific 𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 curated and authored 𝗯𝘆 𝗯𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 experts and medical 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 pursuing the quest to make the latest research available to healthcare professionals and accessible to the Global community of biological scientists and practicing physicians and medical students.
Now, 𝘄𝗵𝘆 𝗹𝗶𝗺𝗶𝘁 𝘁𝗵𝗲𝗶𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝗼𝗻𝗹𝘆 𝘁𝗼 𝗮𝗻 𝗘𝗻𝗴𝗹𝗶𝘀𝗵-𝘀𝗽𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲?
With 471,000 million speakers in 22 countries, the Spanish language was the most relevant language to publish a new edition.
So, it was time to find the right #LanguageServiceProvider. Dr. Lev-Ari first contacted:
1️⃣ A company that couldn’t handle the project due to its size.
2️⃣ Another provider whose quote they couldn’t accept.
This led LPBI to adjust the scope of work and set certain boundaries, such as the budget for the project and making the decision that the project will focus on translation of the cover page of 18 e-books and the electronic Table of Contents (eTOCs) of these e-Books.
And then Aviva came across Fritz Handtke and Montero on LinkedIn. We held a couple of meetings to:
🤝 Define the scope of the project.
🤝 Create a methodology we could repeat 18 times.
🤝 Show LPBI how we work, including the software used to avoid counting (and charging for) repeated words.
🤝 Introduce our experts in the medical field to them.
Aviva’s acceptance of our quote marked the beginning of a very smooth collaboration.
It took us less than five months, involving three #MedicalTranslators, to deliver the eTOCs in Spanish (for 𝟭𝟵 𝗯𝗼𝗼𝗸𝘀 divided into five series).
The result of this project was “a new genre of the original #biomed e-Series.” In each volume of the Spanish-language Edition: PART A is Spanish audios, PART B is Bilingual texts, and PART C is editorials in English.
- Serie A: Enfermedades cardiovasculares – Six volumes
- Serie B: Fronteras de la investigación genómica – Three volumes [One new book in the Spanish-language Edition]
- Serie C: Cáncer y la oncología – Two volumes
- Serie D: Biomedicina. Metabolómica, inmunología, enfermedades infecciosas, genómica reproductiva y endocr – Four volumes [volume 2 and volume 3 are separate books]
- Serie E: Medicina centrada en el paciente – Four volumes
When we asked Dr. Lev-Ari about her experience with Montero, she highlighted the following points:
1️⃣ “At all times, there was 𝗼𝗻𝗲 𝘀𝗶𝗻𝗴𝗹𝗲 𝗽𝗲𝗿𝘀𝗼𝗻 𝗮𝘀𝘀𝗶𝗴𝗻𝗲𝗱 𝘁𝗼 𝗺𝘆 𝗽𝗿𝗼𝗷𝗲𝗰𝘁.”
2️⃣ “One of the editors of the series A in cardiovascular is a Spanish-speaking cardiologist. He reviewed 2 books and confirmed the 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆.”
3️⃣ “Their 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝘁𝗶𝗺𝗲 was most favorable. After submitting a file, I got the translation within a week. For any questions, I’d receive a timely response.”
Imagine how thrilled we were to hear her say:
“Congratulations to Montero because they delivered a very monumental project. Without our collaboration, that would have most likely not have happened.”
Thanks to Aviva and LPBI Group for your trust in Montero!
You can find all 37 books here
👇
https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
FRASE IMAGEN
“I needed a partner that I could rely on for quality, interactivity, timing and budget. Montero was outstanding on all these counts.”
UPDATED on 1/28/2023
Testimonial by Prof. Marcus W. Feldman, Stanford University, Biology Department, 1/27/2023
In the past ten years LPBI Group has accomplished an enormous amount in the domain of electronic scientific publishing. Under the direction of its founder, Dr. Aviva Lev-Ari, LPBI Group introduced a methodology to curate scientific findings reported in medical and biological publications. The curation of these findings with clinical interpretations by experts was designed to make these publications in research journals accessible and comprehensible to students and health professionals beyond the subscribers to the journals in which these articles first appeared. It is a multi-authoring system for content creation on the WordPress.com cloud platform, which was originally designed for single-author blogs and websites. Dr. Lev-Ari expanded the use of the platform from a single-authoring to a multi-authoring system. LPBI Group’s website is the only one functioning at that level on WordPress.com.
These curations were collected in eighteen English-language (2013-2021) and nineteen Spanish-language volumes (2022-2023). These 37 volumes include 2,728 articles by an excellent team of biomedical professionals whom Dr. Lev-Ari personally recruited to join the team of experts, authors, and writers (EAWs). Dr. Lev-Ari contributed to each volume, and in general, 58.7% of all articles in the journal (3,618 articles) represent her contributions. The articles in the e-books were initially published in the open access online scientific journal “PharmaceuticalIntelligence.com” launched by Dr. Lev-Ari in April 2012. In 2023 there are over 6,150 articles in the journal enjoying more than 2.2MM views. The articles in the e-books were selected for inclusion in each volume by the volume’s editor. Thus, only 44.4% of all articles in the journal are included in the e-books. Less than 10% of the articles included in the e-books are included in more than one volume in the BioMed e-Series. The 18 English-language books have had more than 140,000 page downloads up to 12/31/2022.
Topics covered in the collections include cardiovascular diseases and therapies, genomics, cancer etiology and therapies, immunology, and patient-centered studies with a focus on precision medicine. Together these eighteen volumes constitute an invaluable library of biomedical information that can greatly enhance medical education and provide a resource for updating and continuing education for practicing health care professionals.
Dr. Lev-Ari took the lead in assembling an eminent team of scholars who, together with herself, contributed to the curations that produced the 2,728 articles included in the 18 volumes. Her leadership is exhibited in the choice and commissioning of scholars who contributed curations and in the choice of articles. On a daily basis, article titles were chosen for new curation, and she participated in the production of many of these curations. Dr. Larry H. Bernstein, CSO, also initiated more than 1,000 curation titles and pursued the curation process as single author.
The recent launch of LPBI Group’s BioMed e-Series in the Spanish language, accomplished via a collaboration with Montero Language Services, Madrid, Spain, was overseen by Dr. Lev-Ari and promises to make LPBI’s library of biomedical knowledge available to thousands of students and professionals in the Spanish-speaking world, a remarkable achievement.
Prof. Marcus W. Feldman
Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences at Stanford University and co-director of Stanford Bio-X, the Stanford Cancer Institute, the Stanford Neurosciences Institute and the Stanford Woods Institute for the Environment.
Testimonial by Dr. Larry H. Bernstein, MD, FCAP, 1/8/2023
Leaders in Pharmaceutical Business Intelligence (LPBI) Group has published a series of BioMed e-books that cover in serious detail the developments in medical and pharmaceutical science of significant importance. The work on the BioMed e-Series had several objectives:
- Creation of a source of reference to major cardiovascular, metabolic diseases (diabetes mellitus) that may have a mechanism related to both genetic and dietary factors
- Genetic diseases, infectious disease, immunobiology, and diseases of the endocrine, neurological and reproductive systems, and then,
- Patient-centered care and Precision Medicine
The material has significant depth that would be of considerable promise for coursework in high school AP classes in biology, undergraduate education in the Biological Sciences. The volume and depth of the material is optimal for medical students, as well. The books cover an entire array of healthcare knowledge and current research curated articles useful for research scientists, doctors, university students as well as for the common public. It is a voluminous database to look for and refer for any kind of healthcare related information and research in related fields of biology. These volumes of clinical interpretation of scientific findings are a treasure for any library and digital repository in life sciences and medical science.
The work that went into this project is to be credited with the work of a number of authors with medical and advanced degrees in the Biological Sciences. The content was organized by the series Editor-in-Chief, Dr. Aviva Lev Ari, with contributions by selected professionals. I give credit to the several members of this undertaking, which has a unique identity unlike any that I am aware of.
The books are published in both English and Spanish.
Sincerely,
Larry H. Bernstein, MD
Retired – Chief of the Division of Clinical Pathology at New York Methodist Hospital-Weill Cornell Affiliate in Brooklyn, New York. Chief of Clinical Chemistry and Chief of the Blood Bank at Bridgeport Hospital, Connecticut and Acting Chairperson of Yale University’s Department of Pathology at Bridgeport Hospital.
Testimonial by Dr. Stephen J. Williams, PhD, 2/7/2023
Leaders in Pharmaceutical Business Intelligence (LBPI Group), launched in April 2012 as an Open Access Online Scientific Journal (http://pharmaceuticalintelligence.com), has reached over 2 million unique site visits, with approximately 30,000 monthly views, 1,600 followers and 300 sites linking into the journal, including ncbi.nlm.nih.gov, Nature.com , commons.wikipedia.org, dx.doi.org, NEJM, personalizedmedicine.partners.org, cancer.gov, medscape.com, masspec.scripps.edu, and sciencedirect.com.
LPBI Group is a scientific, medical and business multi-expert authoring platform in several domains: life sciences, pharmaceutical, healthcare & medical industries. The venture operates as an online scientific intellectual exchange at its website http://pharmaceuticalintelligence.com for curation and reporting on innovations in biomedical and biological sciences, healthcare economics, pharmacology, pharmaceutical research & medicine. The Open Access Online Scientific Journal currently contains over 6,150 annotated & curated articles in over 750 categories of research in Biotech, Life Sciences and Medicine.
The LPBI Group venture publishes a BioMedical Series of e-Books available on mobile platforms (current & future titles at http://pharmaceuticalintelligence.com/biomed-e-books/.) It also represents a dozen Biotechnology and Medical Devices startups in Private Equity Funding and an IP Development Group, DrugDiscovery@LPBI Group, and Medical 3D Printing.
The venture’s expertise in Real-Time Scientific Conferences Coverage, using social media and creating electronic conference proceedings posted on the Internet, has included the following events as well as many others, a total of 100 Global Conferences were covered in real time. The complete list is found here
Among the conferences are the following:
Harvard’s Personalized Medicine Conferences in 2015 & 2016, CHI Discovery On Target 2016, MassBio 2015 & 2016, MassBio Annual Meeting 2014, BioIT World, April 30, 2014, Koch Institute for Integrative Cancer Research @MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014, Gabbay Award Lectures in Biotechnology and Medicine – Hosted by Rosenstiel Basic Medical Sciences Research Center, Brandeis University, October 27, 2014, 10th Annual Personalized Medicine Conference at the Harvard Medical School, November 12-13, 2014, and two Biotech Investment Conferences in 2014, one in NYC and one in Basel by Sachs Associates of London.
The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharmaceutical industries, to the tune of millions of dollars per year. These issues have driven the need for a more context-driven architecture for knowledge and discourse within the biomedical arena. The process of curation decreases time for assessment of current trends adding multiple insights, analyses WITH an underlying METHODOLOGY, provides insights from WHOLE scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data, reporting of findings.
LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process establishes new connections and produces new and transformative ideas.
Using our methodology, LPBI has produced an open-access online scientific journal, a series of 37 BioMed e-books, including Spanish Edition of said BioMed e-books, and Real-time press coverage of scientific conferences, two volumes were optimized for analysis using AI and Natural Language Processing models including code developed by LPBI Group.
Since 2012, the open access journal has been a preeminent validated and trusted source of biomedical knowledge and reporting resource for the most recent cutting edge discoveries and advancements in the fields of biomedicine and biotechnology. Some highlights since then were the first medical e-book published on the use of 3D bio-printing technology for biomedical applications, the most comprehensive publications on personalized medicine and new genomics technologies, the most complete medical source on the physiological and pathological effects of nitric oxide, and one of the most comprehensive e-Series of medical books on cardiovascular disease.
The translation of these BioMed Series of e-books into the Spanish language represents a first in medical education and a critical resourse for an underserved population in the world.
The journal, as well as the ebooks accolades are testified by the numerous comments of our readership as well as the visibility that LPBI has in the scientific community, including the many referenced material of LPBI in the peer reviewed scientific literature.
- At multiple conferences, I personally have been told that people are using our open access journal as a trusted source of scientific news and information. In addition, many high level scientists have appreciated the LPBI platform for disseminating scientific findings and the quality and expansiveness of our offerings, especially in newer fields of biotechnology.
LPBI Group has continually expanded their horizons, bravely entering into new fields. This aspect makes our open access journal as well as e-books a perfect source of information for the development of new course curriculums as well as a trusted, and useful source for professors to expand their current course curriculum.
- I can testify personally that I have used LPBI material to enhance multiple courses at Temple University and
- we have similar testimonial from professors from other Universities as well.
- I have also personal testimonials of people who have appreciated our real time conference coverage, especially in the times of the COVID pandemic, where getting good information was hindered by in-accessibility.
- In fact, during the pandemic as professors scrambled to provide online learning, the LPBI platform was well suited to bridge a gap of online learning material.
On a personal note,
- LPBI’s platform has been an invaluable resource in my own scientific education. The ability to have access to a wide array of scientific expertise who use the LPBI platform has been critical in the development of many of the coursework I have created and in the continued development of my scientific career. In particular,
- the use of the LPBI platform has allowed for critical discourse between me and my colleagues in multiple areas within oncology. One instance in particular was the ability to use the online platform to organize oncologists to discuss how best to serve patients safely during the pandemic shutdown as well as offering a way to communicate scientific panel discussions to those patients affected. These early discussions in the start of the pandemic helped, I believe, many best practices, that were implemented during the pandemic.
- I also received many thanks from patient advocacy groups who were searching for trusted sources of information to guide them through this difficult time.
- Our Coronavirus Portal launched on 3/14/2020 was among the first resources on the eight topics it covered:
https://pharmaceuticalintelligence.com/coronavirus-portal/
Dr. Stephen J. Williams, PhD
Investigator at The ISOPROG-Somatolink EPFP Research Network, School of Medicine, Temple University, Philadelphia, PA
Testimonial by Dr. Sudipta Saha, PhD, 1/18/2023
It is indeed a huge achievement to publish 37 volumes of e-books in English and Spanish. The books cover almost all the areas of healthcare and health related biology knowledge. This collection of e-Books form LPBI Group’s BioMed e-series which is highly helpful to life science students and the research community for easy access to huge amount of information and reference. The access to the articles in LPBI Group’s Journal had reached in 2023 2.2MM views. The pattern and lucidness of curation will also be helpful for the public at large to better understand complicated health related matters. The publication in the languages English and Spanish will cover major part of the world population and make the information available to all. These e-books are going to be handy tools for many who wants to do research or even just read interesting health-related content.
Dr. Sudipta Saha, PhD
Associate Professor at Department of Biotechnology and Microbiology, Sister Nivedita University, Kolkata.
UPDATED on 1/15/2023
Acknowledgements by Dr. Larry in Series E, Volume 3
I congratulate Dr. Aviva Lev-Ari for guiding the completion of this work and assuring continuity from one chapter to the next, and within chapters, and for relevant chapter contributions. Composing the material required searches of a large number of keyword combinations in Scopus/ScienceDirect as well as articles posted in Publications of Pharmaceutical Intelligence. In searching for combinations of therapeutics, genomics, and physiology, the results were overlapped. Special appreciation is extended to Dr. Stephen J. Williams for his design of the header-graphic, but also for his insights into the pharmaceutical industry. Appreciation is also extended to Dr. Demet Sag for her insights into genomics.
2022
UPDATED on 12/31/2022
From: “Ofer Markman, PhD” <oferm2020@gmail.com>
Date: Saturday, December 31, 2022 at 10:38 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Dear Aviva,
As I bid farewell and say goodbye to 2020, 2021, and 2022, I want to express my deepest gratitude for the three exceptional years I was an advisor to Leaders in Pharmaceutical Business Intelligence. During this time, I was able to gain valuable insights and learn from the best of the best, experience and knowledge that I will carry with me in my future endeavors, and hoping to see LPBI thrive as well!
Friendly and with love
Dr. Ofer Markman
Dr. Ofer Markman
Mobile: +972-52-3275720
E-mail:oferm2020@gmail.com
UPDATED on 11/15/2022
Yash Choudhary, IIT, Kanpur, Uttar Pradesh, India
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
PharmaceuticalIntelligence.com
Internship Remarks
Date: Sunday, November 13, 2022 at 4:06 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: How are you ?
Hi Aviva Mam,
I hope all is well with you.
- How are everyone at LPBI? It’s been quite a long time. I read your emails about amazing work that’s currently going on at LPBI and how LPBI is progressing under your leadership . I was very fortunate to have a mentor like you.
- I also wanted to give you some updates on what I’m planning to do next:- I have only one semester left before I graduate and Instead of going for a PhD directly, I’m thinking of doing a corporate job for 1-2 year. Then after that pursue PhD in Nano-sciences. The reason for this is that doing a Job for 1-2 year will give me some financial stability.
Please let me know what are your thoughts on this.
Thanks
Yash Choudhary
UPDATED on 7/13/2022
Madison Davis
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
PharmaceuticalIntelligence.com
Internship Remarks
13 July 2022
Throughout these past two years, my time here at Leaders in Pharmaceutical Business Intelligence has allowed me to expand my knowledge in Natural Language Processing (NLP) and general experience in the field of Artificial Intelligence. Towards the beginning of my internship, I was offered the experience to get accustomed to storage virtualization through Amazon Web Services (AWS) and use the group’s Genomic-style text as an application on that platform. The majority of my time was spent on topic modeling large sums of scientific papers; through the usage of Wolfram and Python, I was able to make hypergraphs, tree diagrams, and bar diagrams to visually represent summaries of text. Beyond manipulating large amounts of textual data, I myself also learned how to write reports as well from a scientific standpoint.
The organization definitely strives to incorporate both undergraduate and graduate research into its permanent program. While other companies would have side projects for interns to work on,
Series B: Frontiers in Genomics Research
Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
https://www.amazon.com/dp/B08385KF87
and
Series C: e-Books on Cancer & Oncology
Volume One: Cancer Biology & Genomics for Disease Diagnosis.
http://www.amazon.com/dp/B013RVYR2K
Being able to see other people’s coding solutions to NLP enabled me to get used to imagining new algorithms, and when other individuals did not have the coding experience necessary for certain tasks, the internship provided me with a stable platform to explain and write out the concepts in an easy-to-read format. While mentorship is provided on identifying the problems at hand, the interns are provided a more relaxed environment to solve the problems on their own time. This allows the intern to explore coding solutions on their own and serves to truly deepen their understanding of the topics at hand.
UPDATED on 5/24/2022
Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
(e) External Citations
2021
UPDATED on 12/18/2021
From: Madison Davis <madisond2302@gmail.com>
Date: Saturday, December 18, 2021 at 5:41 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Updates
Hi Aviva,
I hope all is going well! Exams were tough but overall went well.
I will turn it into an MS word file when we are ready.
I also wanted to thank you so much for your letter for MIT and your invaluable help with college admissions. This Thursday, I was fortunate enough to have received an acceptance from Harvard!
– Maddie Davis
UPDATED on 9/29/2021
Tweet
MIT Technology Review @techreview
@techreview is the handle of MIT Technology Review Twitter account
This account is followed by 1.1 Million followers. Each ReTWEET shares the retweeted Tweet with 1.1 Million followers. The following reTWEETS by @techreview is the equivalent of 3.3 Millions tweet posts
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 8/1/2021
QUOTES
| «Highest regards for the Israel Investment Summit you organized. I attended virtually from Boston. It was an amazing conference on many counts (…) Your July 27, 2021 – Israel Investment Summit, I would rank it in the top dozen. It is an outstanding achievement.» Aviva Lev-Ari, PhD, RN, Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group |
| SOURCE: https://ws.eventact.com/IIS2021/Quotes |
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,
Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.
It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –
Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)
Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO
Any other questions please don’t hesitate to reach out!
All the best,
Charlotte
2020
Updated on 8/25/2020
From: Robin Neff Clebnik <robin@internboston.com>
Date: Tuesday, August 25, 2020 at 5:23 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Thank You!
Hi Aviva,
Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.
By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.
We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.
Best,
Robin
robin neff clebnik
Chief Internship Officer
t: 617.527.0055
m: 617.875.4614
Updated on 8/23/2020
The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:
I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r
the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.
That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.
I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors.
Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources:
- The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RNWith heartfelt gratitude to our Dear Dr. Larry
Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:
- Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series
Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- My Memories Tell a Story to Share
Author: Larry Howard Bernstein, MD, FCAP
Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
Updated on 8/11/2020
The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation
The Voice of Internship Team’s Captain, Daniel, Menzin:
LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.
The Voice of Noam Steiner Tomer:
Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!
The Voice of Zach Day:
This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research. In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings. I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari.
Updated on 6/3/2020
Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award
Reporter: Gail S. Thornton, M.A.
Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.
In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology, at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.
###
Updated on 5/7/2020
From: Alan Kaul <alan@mom-inc.us>
Date: Thursday, May 7, 2020 at 9:03 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Vinit Nair <vinit@pracnet.org>
Subject: Pharmaceutical Intelligence
HI Aviva,
You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.
[ see www.mom-inc.us ]
This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.
I hope that this link will prove helpul to both of us
Stay safe,
Alan
Updated on 4/19/2020
ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020
“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”
Sincerely,
Larry Bernstein, MD
“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”
https://lnkd.in/ekWGNqA
In:
My Memories Tell a Story to Share, 4/19/2020
Author: Larry Howard Bernstein, MD, FCAP
Contact: 413-727-8523
Updated on 2/9/2020
Obtained by Gail S. Thornton on 2/7/2020
Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators.
In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field.
I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology.
—Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.
Updated on 1/31/2020
Notifications from ResearchGate
Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Apr 6, 2019
Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 27, 2018
Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 29, 2018
Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 27, 2018
Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Oct 10, 2016
Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jan 9, 2016
Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I
Dec 12, 2015
UPDATED on 1/10/2020
The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
Dr. Marcus Feldman
Professor of Biology, Stanford University
Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”
Dr. Justin Pearlman
Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist
Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications. He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”
Dr. Stephen Williams
Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University
Dr. Williams has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.
It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”
He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”
Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org
She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”
11/27/2019
Dear Aviva,
Thank You note from sandraleebatista@yahoo.com
Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.
We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.
Best wishes,
Sandra
5/29/2019
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 3:13 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Wednesday, May 29, 2019 12:46 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari
Subject: Re: Permission to reprint image
Dear Prof. Klein,
Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.
It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.
See
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions:
A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]
B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication
C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above
Regarding re-publishing the figure:
I am suggesting to add the following comment:
Image Source:
Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP
https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/
I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.
Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.
Please keep in touch and I encourage you to continue to search our Journal archive.
Best regards,
PS
This e-mail is your e-written permission to re-publish figure as commented, above.
Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 9:12 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you so much Aviva.
The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.
The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.
Appreciatively,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Tuesday, May 28, 2019 12:17 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman
Subject: Re: Permission to reprint image
Dear Prof. Klein,
It is always most endearing to correspond with another fellow Alumna of Berkeley.
Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.
Thank you for reaching out to me for permission to reprint a figure.
Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com
Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com
I will then research and grant you re-printing permission in e-writing.
Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:
1.You may find of interest the following e-Books of ours
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
Series C: e-Books on Cancer & Oncology
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
2. My articles on medical OUTCOMES of Radiation Biology on Cardiotoxicity
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Curator: Aviva Lev-Ari, PhD, RN
3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
Reporter: Aviva Lev-Ari, PhD, RN
2019
http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/
My Journal on Cardiotoxicity on Scoop.it
https://www.scoop.it/topic/cardiotoxicity
Looking forward to getting name of article when the figure had appeared in our publications.
Good luck,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Tuesday, May 28, 2019 at 11:11 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Permission to reprint image
Hello Aviva Lev-Ari,
I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!
Regards,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
(another Berkeley alum)
April 2019
2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19
via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
4/21/2019
From: Amnon Danzig <amnon.danzig@gmail.com>
Date: Sunday, April 21, 2019 at 4:17 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: A Letter from Amnon Danzig
Dear Aviva
Now, I read the two docs in depth.
Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…
It is my honor to work with you and the team.
I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.
I would like to thank you for your very fine and warm words about my contribution. GREAT!
I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.
Why?
My thinking was always going to the ways to present LPBI Group the best it can.
I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.
Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.
I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!
Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.
If you happen to have ideas for me, great.
This is the reason I extend my time in NYC.
BR
Amnon
@@@@@
4/19/2019
LPBI Group: The Business Opportunity
Voice of Prof. Marcus W. Feldman
The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.
@@@@@
4/19/2019
LPBI Group: The Business Plan
Voice of Aviva Lev-Ari, Founder
The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).
- The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD).
- The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
- They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
- Further development of this Business Plan document will follow in the near future.
This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.
This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.
@@@@@
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
@@@@
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags 
to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI@PHSInnovation @ChrisMarkCOBURN 
http://bit.ly/WMIF19
@@@@
Top influencer 3rd place @AVIVA1950
sjwilliamspaThis is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.
https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125
@@@@
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, April 10, 2019 at 10:16 PM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>
Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph
Well done! 3rd place for #WMIF19 is good
See
Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
@@@@
From: Leny <gochevav@mit.edu>
Date: Wednesday, November 28, 2018 at 11:30 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN
Dear Dr. Lev-Ari,
I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.
To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets -> select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.
Please do not hesitate to reach out if you have any additional questions.
Best,
Leny
Vasilena Gocheva, PhD | Assistant Director | MIT Center for Precision Cancer Medicine | 77 Massachusetts Avenue, 76-353 | Cambridge, MA 02139 | cpcm.mit.edu
From: Shankar Khatkale <shankar.k@gminsights.com>
Date: Tuesday, November 27, 2018 at 6:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Article Submission Request
Dear Editor,
An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.
News Link: https://www.gminsights.com/pressrelease/precision-medicine-market
Looking forward to hear from you.
On behalf of and as instructed by Global Market Insights, Inc.
Best Regards,
Shankar Khatkale |SEO Executive
From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>
Date: Monday, October 29, 2018 at 9:33 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Post retirement doctors establishing new career heights – Story Consideration
Dear Aviva,
Would you be interested in interviewing personalities in the medical Fraternity?
Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.
Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education.
I have attached the award letter to this email for your information.
Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.
Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.
Best regards,
Daphne
Executive
Corporate Communications
DID (65) 6705 2769
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Friday, June 1, 2018 at 3:26 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>
Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again
Dear Dr. Lev-Ari,
Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.
I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.
Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!
Best,
Nathan
PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.
From: “Prof. Michael Watts” <mwatts@berkeley.edu>
Date: Sunday, May 13, 2018 at 1:29 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University
Dear Aviva: a very long time! Nice to hear from you and your later extraordinary career! And it seems like you are now on Phase IV. Very exciting.
I am retiring in June but will of course keep writing and conducting research.
You may have heard that Allan’s wife Hjordis passed away relatively recently. It was nice to see their children again at the memorial.
Warmly, Michael
On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:
See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down
If interested to read more, click on:
Aviva’s books on AMAZON.COM
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Dear Professors, Watts, Walker, Sayre, Laguerr and Segev,
I hope you are well and will enjoy the months of Summer coming up.
We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.
I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.
It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.
I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Please Read these two:
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
I attended the 1998 – 100 years Geography Department celebration.
Please review the following, it can be included in the future Itinerant Geographer.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Thank you – Good Luck to you
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Thursday, March 8, 2018 at 6:07 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago
Dear Aviva,
Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.
You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.
Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.
It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:
Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.
Best,
Nathan
On Monday, July 24, 2017 at 9:27 PM
From: marzan Khan <marzan.khan@mail.mcgill.ca>
Date: Monday, July 24, 2017 at 9:27 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2
Hello Aviva,
Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.
Best of luck on the e-book and all your endeavors.
Sincerely,
Marzan Khan
On June 18, 2017, 9;39AM
Dear Aviva Lev-Ari,
Thank you very much for your email.
First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.
I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.
Sincerely from Beijing
Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg
On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:
Hi Aviva,
Thanks! I am also excited to join Regeneron.
Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.
Best
Anamika Sarkar, PhD
@@@@@@
From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>
Date: Wednesday, April 27, 2016 at 11:32 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Thanks Aviva.
You obviously work hard on this!
Keep up the hard work.
Mark
MARK COBBOLD, MD, PHD
From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
LinkedIn Profile Twitter Profile
@@@@@
From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>
Date: Friday, March 18, 2016 at 11:46 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>
Subject: RE: REVOTEK follow up for 3D printing – AVIVA
Hello Aviva:
To answer your questions:
The ownership at regenHU is as is.
The CEO of regenHU is Mr. Marc Thurner
The other CPA Group companies are unchanged i.e. no updates
With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.
I truly hope we can work together since I’m impressed with your activities. Have a great weekend.
Regards,
Tony
Tony Arquisch
Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch
CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre
Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch
LinkedIn Profile / XING Profile / Twitter Profile
@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: February 19, 2016 at 3:40:19 PM EST
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>
Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Dr. Lev-Ari:
Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision.
By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders.
Have a good weekend.
Very sincerely,
Chris
Christopher J. Wells, M.P.A.
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog: Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@
2/12/2016
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination
| Book Title: * | Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
| Publisher(s): * | Amazon Kindle Direct |
| Publication Date: (Please select one): * | November 2015 |
| Book Entry Summary (Please limit to 100 words): * | The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
@@@@@@@
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
@@@@@@@@@
From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>
Date: Tuesday, January 19, 2016 at 1:09 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence
Wow!!!!! That’s very impressive. So proud of being part of this group and project. Good job everyone.
Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.
Good job everyone!!!
Best
Tilda
@@@@@@@@@
From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>
Date: Sunday, January 10, 2016 at 6:13 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: Re: big data start up for you to talk to…
Dear Aviva,
Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!
Gregory
On 1/9/2016, I wrote to Gregory:
My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:
– Journal, ~4000 articles archived, 900,000 e-Readers
– e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016
– Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.
In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using
- BioMEMS for Gene Editing
- BioMEMS for Tissue Engineering
- BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.
We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.
@@@@@@@@
Please see #3
Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP
16 NOV 5 FOR TODAY
Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share
- Responsible innovation in health care and dual use research. [ Health Kid ]
- A patient’s point of view. [ HRBR ]
- Drivers of Patient Experience. [ LPBI ]
- 5 ways providers can improve the patient experience. [ FierceHealthIT ]
- Telehealth is essential to lowering readmission rates. [ mHealthNews ]
@@@@@@@@
From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Date: Friday, November 13, 2015 at 10:14 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Invitation
|
@@@@@@@@@
From: Anne Sim <georgeclinicalau@gmail.com>
Date: Monday, August 3, 2015 at 3:39 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: contributing
Hello,
I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.
We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.
We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.
Thanks,
Anne Sim
@@@@@@@@@@@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: Wednesday, September 2, 2015 at 11:36 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Thank you for re-blogging our post
Hi Dr. Lev-Ari:
I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful.
I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine.
Thank you again.
Sincerely,
Chris
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog:Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@@@@@@@@@@@
Testimonials about LPBI
2021
UPDATED on 9/29/2021
Tweet
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,
Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.
It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –
Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)
Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO
Any other questions please don’t hesitate to reach out!
All the best,
Charlotte
2020
Updated on 8/25/2020
From: Robin Neff Clebnik <robin@internboston.com>
Date: Tuesday, August 25, 2020 at 5:23 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Thank You!
Hi Aviva,
Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.
By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.
We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.
Best,
Robin
robin neff clebnik
Chief Internship Officer
t: 617.527.0055
m: 617.875.4614
Updated on 8/23/2020
The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:
I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r
the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.
That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.
I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors.
Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources:
- The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RNWith heartfelt gratitude to our Dear Dr. Larry
Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:
- Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series
Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- My Memories Tell a Story to Share
Author: Larry Howard Bernstein, MD, FCAP
Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
Updated on 8/11/2020
The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation
The Voice of Internship Team’s Captain, Daniel, Menzin:
LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.
The Voice of Noam Steiner Tomer:
Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!
The Voice of Zach Day:
This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research. In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings. I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari.
Updated on 6/3/2020
Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award
Reporter: Gail S. Thornton, M.A.
Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.
In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology, at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.
###
Updated on 5/7/2020
From: Alan Kaul <alan@mom-inc.us>
Date: Thursday, May 7, 2020 at 9:03 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Vinit Nair <vinit@pracnet.org>
Subject: Pharmaceutical Intelligence
HI Aviva,
You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.
[ see www.mom-inc.us ]
This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.
I hope that this link will prove helpul to both of us
Stay safe,
Alan
Updated on 4/19/2020
ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020
“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”
Sincerely,
Larry Bernstein, MD
“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”
https://lnkd.in/ekWGNqA
In:
My Memories Tell a Story to Share, 4/19/2020
Author: Larry Howard Bernstein, MD, FCAP
Contact: 413-727-8523
Updated on 2/9/2020
Obtained by Gail S. Thornton on 2/7/2020
Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators.
In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field.
I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology.
—Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.
Updated on 1/31/2020
Notifications from ResearchGate
Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Apr 6, 2019
Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 27, 2018
Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 29, 2018
Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 27, 2018
Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Oct 10, 2016
Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jan 9, 2016
Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I
Dec 12, 2015
UPDATED on 1/10/2020
The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
Dr. Marcus Feldman
Professor of Biology, Stanford University
Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”
Dr. Justin Pearlman
Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist
Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications. He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”
Dr. Stephen Williams
Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University
Dr. Williams has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.
It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”
He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”
Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org
She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”
11/27/2019
Dear Aviva,
Thank You note from sandraleebatista@yahoo.com
Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.
We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.
Best wishes,
Sandra
5/29/2019
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 3:13 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Wednesday, May 29, 2019 12:46 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari
Subject: Re: Permission to reprint image
Dear Prof. Klein,
Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.
It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.
See
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions:
A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]
B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication
C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above
Regarding re-publishing the figure:
I am suggesting to add the following comment:
Image Source:
Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP
https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/
I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.
Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.
Please keep in touch and I encourage you to continue to search our Journal archive.
Best regards,
PS
This e-mail is your e-written permission to re-publish figure as commented, above.
Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 9:12 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you so much Aviva.
The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.
The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.
Appreciatively,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Tuesday, May 28, 2019 12:17 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman
Subject: Re: Permission to reprint image
Dear Prof. Klein,
It is always most endearing to correspond with another fellow Alumna of Berkeley.
Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.
Thank you for reaching out to me for permission to reprint a figure.
Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com
Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com
I will then research and grant you re-printing permission in e-writing.
Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:
1.You may find of interest the following e-Books of ours
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
Series C: e-Books on Cancer & Oncology
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
2. My articles on medical OUTCOMES of Radiation Biology on Cardiotoxicity
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Curator: Aviva Lev-Ari, PhD, RN
3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
Reporter: Aviva Lev-Ari, PhD, RN
2019
http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/
My Journal on Cardiotoxicity on Scoop.it
https://www.scoop.it/topic/cardiotoxicity
Looking forward to getting name of article when the figure had appeared in our publications.
Good luck,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Tuesday, May 28, 2019 at 11:11 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Permission to reprint image
Hello Aviva Lev-Ari,
I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!
Regards,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
(another Berkeley alum)
April 2019
2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19
via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
4/21/2019
From: Amnon Danzig <amnon.danzig@gmail.com>
Date: Sunday, April 21, 2019 at 4:17 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: A Letter from Amnon Danzig
Dear Aviva
Now, I read the two docs in depth.
Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…
It is my honor to work with you and the team.
I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.
I would like to thank you for your very fine and warm words about my contribution. GREAT!
I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.
Why?
My thinking was always going to the ways to present LPBI Group the best it can.
I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.
Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.
I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!
Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.
If you happen to have ideas for me, great.
This is the reason I extend my time in NYC.
BR
Amnon
@@@@@
4/19/2019
LPBI Group: The Business Opportunity
Voice of Prof. Marcus W. Feldman
The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.
@@@@@
4/19/2019
LPBI Group: The Business Plan
Voice of Aviva Lev-Ari, Founder
The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).
- The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD).
- The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
- They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
- Further development of this Business Plan document will follow in the near future.
This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.
This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.
@@@@@
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
@@@@
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI@PHSInnovation @ChrisMarkCOBURN http://bit.ly/WMIF19
@@@@
Top influencer 3rd place @AVIVA1950
This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.
https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125
@@@@
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, April 10, 2019 at 10:16 PM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>
Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph
Well done! 3rd place for #WMIF19 is good
See
Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
@@@@
From: Leny <gochevav@mit.edu>
Date: Wednesday, November 28, 2018 at 11:30 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN
Dear Dr. Lev-Ari,
I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.
To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets -> select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.
Please do not hesitate to reach out if you have any additional questions.
Best,
Leny
Vasilena Gocheva, PhD | Assistant Director | MIT Center for Precision Cancer Medicine | 77 Massachusetts Avenue, 76-353 | Cambridge, MA 02139 | cpcm.mit.edu
From: Shankar Khatkale <shankar.k@gminsights.com>
Date: Tuesday, November 27, 2018 at 6:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Article Submission Request
Dear Editor,
An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.
News Link: https://www.gminsights.com/pressrelease/precision-medicine-market
Looking forward to hear from you.
On behalf of and as instructed by Global Market Insights, Inc.
Best Regards,
Shankar Khatkale |SEO Executive
From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>
Date: Monday, October 29, 2018 at 9:33 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Post retirement doctors establishing new career heights – Story Consideration
Dear Aviva,
Would you be interested in interviewing personalities in the medical Fraternity?
Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.
Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education.
I have attached the award letter to this email for your information.
Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.
Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.
Best regards,
Daphne
Executive
Corporate Communications
DID (65) 6705 2769
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Friday, June 1, 2018 at 3:26 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>
Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again
Dear Dr. Lev-Ari,
Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.
I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.
Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!
Best,
Nathan
PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.
From: “Prof. Michael Watts” <mwatts@berkeley.edu>
Date: Sunday, May 13, 2018 at 1:29 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University
Dear Aviva: a very long time! Nice to hear from you and your later extraordinary career! And it seems like you are now on Phase IV. Very exciting.
I am retiring in June but will of course keep writing and conducting research.
You may have heard that Allan’s wife Hjordis passed away relatively recently. It was nice to see their children again at the memorial.
Warmly, Michael
On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:
See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down
If interested to read more, click on:
Aviva’s books on AMAZON.COM
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Dear Professors, Watts, Walker, Sayre, Laguerr and Segev,
I hope you are well and will enjoy the months of Summer coming up.
We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.
I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.
It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.
I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Please Read these two:
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
I attended the 1998 – 100 years Geography Department celebration.
Please review the following, it can be included in the future Itinerant Geographer.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Thank you – Good Luck to you
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Thursday, March 8, 2018 at 6:07 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago
Dear Aviva,
Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.
You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.
Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.
It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:
Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.
Best,
Nathan
On Monday, July 24, 2017 at 9:27 PM
From: marzan Khan <marzan.khan@mail.mcgill.ca>
Date: Monday, July 24, 2017 at 9:27 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2
Hello Aviva,
Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.
Best of luck on the e-book and all your endeavors.
Sincerely,
Marzan Khan
On June 18, 2017, 9;39AM
Dear Aviva Lev-Ari,
Thank you very much for your email.
First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.
I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.
Sincerely from Beijing
Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg
On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:
Hi Aviva,
Thanks! I am also excited to join Regeneron.
Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.
Best
Anamika Sarkar, PhD
@@@@@@
From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>
Date: Wednesday, April 27, 2016 at 11:32 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Thanks Aviva.
You obviously work hard on this!
Keep up the hard work.
Mark
MARK COBBOLD, MD, PHD
From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
LinkedIn Profile Twitter Profile
@@@@@
From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>
Date: Friday, March 18, 2016 at 11:46 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>
Subject: RE: REVOTEK follow up for 3D printing – AVIVA
Hello Aviva:
To answer your questions:
The ownership at regenHU is as is.
The CEO of regenHU is Mr. Marc Thurner
The other CPA Group companies are unchanged i.e. no updates
With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.
I truly hope we can work together since I’m impressed with your activities. Have a great weekend.
Regards,
Tony
Tony Arquisch
Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch
CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre
Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch
LinkedIn Profile / XING Profile / Twitter Profile
@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: February 19, 2016 at 3:40:19 PM EST
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>
Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Dr. Lev-Ari:
Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision.
By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders.
Have a good weekend.
Very sincerely,
Chris
Christopher J. Wells, M.P.A.
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog: Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@
2/12/2016
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination
| Book Title: * | Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
| Publisher(s): * | Amazon Kindle Direct |
| Publication Date: (Please select one): * | November 2015 |
| Book Entry Summary (Please limit to 100 words): * | The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
@@@@@@@
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
@@@@@@@@@
From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>
Date: Tuesday, January 19, 2016 at 1:09 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence
Wow!!!!! That’s very impressive. So proud of being part of this group and project. Good job everyone.
Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.
Good job everyone!!!
Best
Tilda
@@@@@@@@@
From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>
Date: Sunday, January 10, 2016 at 6:13 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: Re: big data start up for you to talk to…
Dear Aviva,
Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!
Gregory
On 1/9/2016, I wrote to Gregory:
My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:
– Journal, ~4000 articles archived, 900,000 e-Readers
– e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016
– Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.
In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using
- BioMEMS for Gene Editing
- BioMEMS for Tissue Engineering
- BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.
We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.
@@@@@@@@
Please see #3
Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP
16 NOV 5 FOR TODAY
Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share
- Responsible innovation in health care and dual use research. [ Health Kid ]
- A patient’s point of view. [ HRBR ]
- Drivers of Patient Experience. [ LPBI ]
- 5 ways providers can improve the patient experience. [ FierceHealthIT ]
- Telehealth is essential to lowering readmission rates. [ mHealthNews ]
@@@@@@@@
From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Date: Friday, November 13, 2015 at 10:14 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Invitation
|
@@@@@@@@@
From: Anne Sim <georgeclinicalau@gmail.com>
Date: Monday, August 3, 2015 at 3:39 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: contributing
Hello,
I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.
We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.
We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.
Thanks,
Anne Sim
@@@@@@@@@@@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: Wednesday, September 2, 2015 at 11:36 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Thank you for re-blogging our post
Hi Dr. Lev-Ari:
I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful.
I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine.
Thank you again.
Sincerely,
Chris
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog:Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@@@@@@@@@@@
Testimonials about LPBI
2021
UPDATED on 9/29/2021
Tweet
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,
Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.
It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –
Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)
Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO
Any other questions please don’t hesitate to reach out!
All the best,
Charlotte
2020
Updated on 8/25/2020
From: Robin Neff Clebnik <robin@internboston.com>
Date: Tuesday, August 25, 2020 at 5:23 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Thank You!
Hi Aviva,
Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.
By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.
We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.
Best,
Robin
robin neff clebnik
Chief Internship Officer
t: 617.527.0055
m: 617.875.4614
Updated on 8/23/2020
The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:
I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r
the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.
That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.
I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors.
Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources:
- The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RNWith heartfelt gratitude to our Dear Dr. Larry
Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:
- Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series
Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- My Memories Tell a Story to Share
Author: Larry Howard Bernstein, MD, FCAP
Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
Updated on 8/11/2020
The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation
The Voice of Internship Team’s Captain, Daniel, Menzin:
LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.
The Voice of Noam Steiner Tomer:
Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!
The Voice of Zach Day:
This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research. In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings. I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari.
Updated on 6/3/2020
Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award
Reporter: Gail S. Thornton, M.A.
Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.
In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology, at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.
###
Updated on 5/7/2020
From: Alan Kaul <alan@mom-inc.us>
Date: Thursday, May 7, 2020 at 9:03 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Vinit Nair <vinit@pracnet.org>
Subject: Pharmaceutical Intelligence
HI Aviva,
You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.
[ see www.mom-inc.us ]
This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.
I hope that this link will prove helpul to both of us
Stay safe,
Alan
Updated on 4/19/2020
ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020
“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”
Sincerely,
Larry Bernstein, MD
“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”
https://lnkd.in/ekWGNqA
In:
My Memories Tell a Story to Share, 4/19/2020
Author: Larry Howard Bernstein, MD, FCAP
Contact: 413-727-8523
Updated on 2/9/2020
Obtained by Gail S. Thornton on 2/7/2020
Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators.
In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field.
I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology.
—Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.
Updated on 1/31/2020
Notifications from ResearchGate
Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Apr 6, 2019
Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 27, 2018
Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 29, 2018
Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 27, 2018
Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Oct 10, 2016
Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jan 9, 2016
Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I
Dec 12, 2015
UPDATED on 1/10/2020
The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
Dr. Marcus Feldman
Professor of Biology, Stanford University
Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”
Dr. Justin Pearlman
Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist
Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications. He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”
Dr. Stephen Williams
Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University
Dr. Williams has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.
It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”
He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”
Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org
She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”
11/27/2019
Dear Aviva,
Thank You note from sandraleebatista@yahoo.com
Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.
We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.
Best wishes,
Sandra
5/29/2019
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 3:13 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Wednesday, May 29, 2019 12:46 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari
Subject: Re: Permission to reprint image
Dear Prof. Klein,
Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.
It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.
See
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions:
A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]
B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication
C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above
Regarding re-publishing the figure:
I am suggesting to add the following comment:
Image Source:
Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP
https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/
I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.
Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.
Please keep in touch and I encourage you to continue to search our Journal archive.
Best regards,
PS
This e-mail is your e-written permission to re-publish figure as commented, above.
Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 9:12 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you so much Aviva.
The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.
The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.
Appreciatively,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Tuesday, May 28, 2019 12:17 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman
Subject: Re: Permission to reprint image
Dear Prof. Klein,
It is always most endearing to correspond with another fellow Alumna of Berkeley.
Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.
Thank you for reaching out to me for permission to reprint a figure.
Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com
Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com
I will then research and grant you re-printing permission in e-writing.
Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:
1.You may find of interest the following e-Books of ours
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
Series C: e-Books on Cancer & Oncology
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
2. My articles on medical OUTCOMES of Radiation Biology on Cardiotoxicity
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Curator: Aviva Lev-Ari, PhD, RN
3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
Reporter: Aviva Lev-Ari, PhD, RN
2019
http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/
My Journal on Cardiotoxicity on Scoop.it
https://www.scoop.it/topic/cardiotoxicity
Looking forward to getting name of article when the figure had appeared in our publications.
Good luck,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Tuesday, May 28, 2019 at 11:11 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Permission to reprint image
Hello Aviva Lev-Ari,
I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!
Regards,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
(another Berkeley alum)
April 2019
2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19
via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
4/21/2019
From: Amnon Danzig <amnon.danzig@gmail.com>
Date: Sunday, April 21, 2019 at 4:17 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: A Letter from Amnon Danzig
Dear Aviva
Now, I read the two docs in depth.
Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…
It is my honor to work with you and the team.
I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.
I would like to thank you for your very fine and warm words about my contribution. GREAT!
I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.
Why?
My thinking was always going to the ways to present LPBI Group the best it can.
I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.
Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.
I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!
Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.
If you happen to have ideas for me, great.
This is the reason I extend my time in NYC.
BR
Amnon
@@@@@
4/19/2019
LPBI Group: The Business Opportunity
Voice of Prof. Marcus W. Feldman
The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.
@@@@@
4/19/2019
LPBI Group: The Business Plan
Voice of Aviva Lev-Ari, Founder
The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).
- The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD).
- The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
- They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
- Further development of this Business Plan document will follow in the near future.
This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.
This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.
@@@@@
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
@@@@
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI@PHSInnovation @ChrisMarkCOBURN http://bit.ly/WMIF19
@@@@
Top influencer 3rd place @AVIVA1950
This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.
https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125
@@@@
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, April 10, 2019 at 10:16 PM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>
Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph
Well done! 3rd place for #WMIF19 is good
See
Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
@@@@
From: Leny <gochevav@mit.edu>
Date: Wednesday, November 28, 2018 at 11:30 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN
Dear Dr. Lev-Ari,
I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.
To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets -> select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.
Please do not hesitate to reach out if you have any additional questions.
Best,
Leny
Vasilena Gocheva, PhD | Assistant Director | MIT Center for Precision Cancer Medicine | 77 Massachusetts Avenue, 76-353 | Cambridge, MA 02139 | cpcm.mit.edu
From: Shankar Khatkale <shankar.k@gminsights.com>
Date: Tuesday, November 27, 2018 at 6:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Article Submission Request
Dear Editor,
An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.
News Link: https://www.gminsights.com/pressrelease/precision-medicine-market
Looking forward to hear from you.
On behalf of and as instructed by Global Market Insights, Inc.
Best Regards,
Shankar Khatkale |SEO Executive
From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>
Date: Monday, October 29, 2018 at 9:33 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Post retirement doctors establishing new career heights – Story Consideration
Dear Aviva,
Would you be interested in interviewing personalities in the medical Fraternity?
Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.
Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education.
I have attached the award letter to this email for your information.
Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.
Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.
Best regards,
Daphne
Executive
Corporate Communications
DID (65) 6705 2769
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Friday, June 1, 2018 at 3:26 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>
Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again
Dear Dr. Lev-Ari,
Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.
I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.
Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!
Best,
Nathan
PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.
From: “Prof. Michael Watts” <mwatts@berkeley.edu>
Date: Sunday, May 13, 2018 at 1:29 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University
Dear Aviva: a very long time! Nice to hear from you and your later extraordinary career! And it seems like you are now on Phase IV. Very exciting.
I am retiring in June but will of course keep writing and conducting research.
You may have heard that Allan’s wife Hjordis passed away relatively recently. It was nice to see their children again at the memorial.
Warmly, Michael
On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:
See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down
If interested to read more, click on:
Aviva’s books on AMAZON.COM
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Dear Professors, Watts, Walker, Sayre, Laguerr and Segev,
I hope you are well and will enjoy the months of Summer coming up.
We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.
I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.
It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.
I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Please Read these two:
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
I attended the 1998 – 100 years Geography Department celebration.
Please review the following, it can be included in the future Itinerant Geographer.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Thank you – Good Luck to you
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Thursday, March 8, 2018 at 6:07 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago
Dear Aviva,
Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.
You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.
Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.
It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:
Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.
Best,
Nathan
On Monday, July 24, 2017 at 9:27 PM
From: marzan Khan <marzan.khan@mail.mcgill.ca>
Date: Monday, July 24, 2017 at 9:27 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2
Hello Aviva,
Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.
Best of luck on the e-book and all your endeavors.
Sincerely,
Marzan Khan
On June 18, 2017, 9;39AM
Dear Aviva Lev-Ari,
Thank you very much for your email.
First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.
I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.
Sincerely from Beijing
Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg
On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:
Hi Aviva,
Thanks! I am also excited to join Regeneron.
Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.
Best
Anamika Sarkar, PhD
@@@@@@
From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>
Date: Wednesday, April 27, 2016 at 11:32 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Thanks Aviva.
You obviously work hard on this!
Keep up the hard work.
Mark
MARK COBBOLD, MD, PHD
From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
LinkedIn Profile Twitter Profile
@@@@@
From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>
Date: Friday, March 18, 2016 at 11:46 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>
Subject: RE: REVOTEK follow up for 3D printing – AVIVA
Hello Aviva:
To answer your questions:
The ownership at regenHU is as is.
The CEO of regenHU is Mr. Marc Thurner
The other CPA Group companies are unchanged i.e. no updates
With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.
I truly hope we can work together since I’m impressed with your activities. Have a great weekend.
Regards,
Tony
Tony Arquisch
Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch
CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre
Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch
LinkedIn Profile / XING Profile / Twitter Profile
@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: February 19, 2016 at 3:40:19 PM EST
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>
Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Dr. Lev-Ari:
Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision.
By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders.
Have a good weekend.
Very sincerely,
Chris
Christopher J. Wells, M.P.A.
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog: Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@
2/12/2016
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination
| Book Title: * | Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
| Publisher(s): * | Amazon Kindle Direct |
| Publication Date: (Please select one): * | November 2015 |
| Book Entry Summary (Please limit to 100 words): * | The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
@@@@@@@
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
@@@@@@@@@
From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>
Date: Tuesday, January 19, 2016 at 1:09 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence
Wow!!!!! That’s very impressive. So proud of being part of this group and project. Good job everyone.
Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.
Good job everyone!!!
Best
Tilda
@@@@@@@@@
From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>
Date: Sunday, January 10, 2016 at 6:13 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: Re: big data start up for you to talk to…
Dear Aviva,
Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!
Gregory
On 1/9/2016, I wrote to Gregory:
My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:
– Journal, ~4000 articles archived, 900,000 e-Readers
– e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016
– Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.
In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using
- BioMEMS for Gene Editing
- BioMEMS for Tissue Engineering
- BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.
We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.
@@@@@@@@
Please see #3
Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP
16 NOV 5 FOR TODAY
Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share
- Responsible innovation in health care and dual use research. [ Health Kid ]
- A patient’s point of view. [ HRBR ]
- Drivers of Patient Experience. [ LPBI ]
- 5 ways providers can improve the patient experience. [ FierceHealthIT ]
- Telehealth is essential to lowering readmission rates. [ mHealthNews ]
@@@@@@@@
From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Date: Friday, November 13, 2015 at 10:14 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Invitation
|
@@@@@@@@@
From: Anne Sim <georgeclinicalau@gmail.com>
Date: Monday, August 3, 2015 at 3:39 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: contributing
Hello,
I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.
We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.
We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.
Thanks,
Anne Sim
@@@@@@@@@@@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: Wednesday, September 2, 2015 at 11:36 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Thank you for re-blogging our post
Hi Dr. Lev-Ari:
I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful.
I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine.
Thank you again.
Sincerely,
Chris
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog:Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@@@@@@@@@@@
Testimonials about LPBI
2021
UPDATED on 9/29/2021
Tweet
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,
Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.
It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –
Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)
Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO
Any other questions please don’t hesitate to reach out!
All the best,
Charlotte
2020
Updated on 8/25/2020
From: Robin Neff Clebnik <robin@internboston.com>
Date: Tuesday, August 25, 2020 at 5:23 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Thank You!
Hi Aviva,
Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.
By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.
We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.
Best,
Robin
robin neff clebnik
Chief Internship Officer
t: 617.527.0055
m: 617.875.4614
Updated on 8/23/2020
The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:
I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r
the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.
That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.
I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors.
Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources:
- The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RNWith heartfelt gratitude to our Dear Dr. Larry
Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:
- Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series
Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- My Memories Tell a Story to Share
Author: Larry Howard Bernstein, MD, FCAP
Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
Updated on 8/11/2020
The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation
The Voice of Internship Team’s Captain, Daniel, Menzin:
LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.
The Voice of Noam Steiner Tomer:
Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!
The Voice of Zach Day:
This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research. In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings. I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari.
Updated on 6/3/2020
Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award
Reporter: Gail S. Thornton, M.A.
Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.
In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology, at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.
###
Updated on 5/7/2020
From: Alan Kaul <alan@mom-inc.us>
Date: Thursday, May 7, 2020 at 9:03 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Vinit Nair <vinit@pracnet.org>
Subject: Pharmaceutical Intelligence
HI Aviva,
You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.
[ see www.mom-inc.us ]
This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.
I hope that this link will prove helpul to both of us
Stay safe,
Alan
Updated on 4/19/2020
ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020
“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”
Sincerely,
Larry Bernstein, MD
“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”
https://lnkd.in/ekWGNqA
In:
My Memories Tell a Story to Share, 4/19/2020
Author: Larry Howard Bernstein, MD, FCAP
Contact: 413-727-8523
Updated on 2/9/2020
Obtained by Gail S. Thornton on 2/7/2020
Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators.
In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field.
I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology.
—Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.
Updated on 1/31/2020
Notifications from ResearchGate
Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Apr 6, 2019
Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 27, 2018
Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 29, 2018
Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 27, 2018
Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Oct 10, 2016
Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jan 9, 2016
Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I
Dec 12, 2015
UPDATED on 1/10/2020
The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
Dr. Marcus Feldman
Professor of Biology, Stanford University
Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”
Dr. Justin Pearlman
Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist
Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications. He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”
Dr. Stephen Williams
Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University
Dr. Williams has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.
It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”
He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”
Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org
She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”
11/27/2019
Dear Aviva,
Thank You note from sandraleebatista@yahoo.com
Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.
We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.
Best wishes,
Sandra
5/29/2019
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 3:13 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Wednesday, May 29, 2019 12:46 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari
Subject: Re: Permission to reprint image
Dear Prof. Klein,
Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.
It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.
See
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions:
A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]
B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication
C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above
Regarding re-publishing the figure:
I am suggesting to add the following comment:
Image Source:
Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP
https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/
I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.
Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.
Please keep in touch and I encourage you to continue to search our Journal archive.
Best regards,
PS
This e-mail is your e-written permission to re-publish figure as commented, above.
Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 9:12 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you so much Aviva.
The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.
The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.
Appreciatively,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Tuesday, May 28, 2019 12:17 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman
Subject: Re: Permission to reprint image
Dear Prof. Klein,
It is always most endearing to correspond with another fellow Alumna of Berkeley.
Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.
Thank you for reaching out to me for permission to reprint a figure.
Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com
Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com
I will then research and grant you re-printing permission in e-writing.
Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:
1.You may find of interest the following e-Books of ours
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
Series C: e-Books on Cancer & Oncology
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
2. My articles on medical OUTCOMES of Radiation Biology on Cardiotoxicity
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Curator: Aviva Lev-Ari, PhD, RN
3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
Reporter: Aviva Lev-Ari, PhD, RN
2019
http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/
My Journal on Cardiotoxicity on Scoop.it
https://www.scoop.it/topic/cardiotoxicity
Looking forward to getting name of article when the figure had appeared in our publications.
Good luck,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Tuesday, May 28, 2019 at 11:11 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Permission to reprint image
Hello Aviva Lev-Ari,
I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!
Regards,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
(another Berkeley alum)
April 2019
2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19
via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
4/21/2019
From: Amnon Danzig <amnon.danzig@gmail.com>
Date: Sunday, April 21, 2019 at 4:17 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: A Letter from Amnon Danzig
Dear Aviva
Now, I read the two docs in depth.
Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…
It is my honor to work with you and the team.
I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.
I would like to thank you for your very fine and warm words about my contribution. GREAT!
I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.
Why?
My thinking was always going to the ways to present LPBI Group the best it can.
I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.
Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.
I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!
Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.
If you happen to have ideas for me, great.
This is the reason I extend my time in NYC.
BR
Amnon
@@@@@
4/19/2019
LPBI Group: The Business Opportunity
Voice of Prof. Marcus W. Feldman
The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.
@@@@@
4/19/2019
LPBI Group: The Business Plan
Voice of Aviva Lev-Ari, Founder
The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).
- The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD).
- The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
- They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
- Further development of this Business Plan document will follow in the near future.
This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.
This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.
@@@@@
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
@@@@
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI@PHSInnovation @ChrisMarkCOBURN http://bit.ly/WMIF19
@@@@
Top influencer 3rd place @AVIVA1950
This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.
https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125
@@@@
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, April 10, 2019 at 10:16 PM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>
Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph
Well done! 3rd place for #WMIF19 is good
See
Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
@@@@
From: Leny <gochevav@mit.edu>
Date: Wednesday, November 28, 2018 at 11:30 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN
Dear Dr. Lev-Ari,
I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.
To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets -> select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.
Please do not hesitate to reach out if you have any additional questions.
Best,
Leny
Vasilena Gocheva, PhD | Assistant Director | MIT Center for Precision Cancer Medicine | 77 Massachusetts Avenue, 76-353 | Cambridge, MA 02139 | cpcm.mit.edu
From: Shankar Khatkale <shankar.k@gminsights.com>
Date: Tuesday, November 27, 2018 at 6:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Article Submission Request
Dear Editor,
An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.
News Link: https://www.gminsights.com/pressrelease/precision-medicine-market
Looking forward to hear from you.
On behalf of and as instructed by Global Market Insights, Inc.
Best Regards,
Shankar Khatkale |SEO Executive
From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>
Date: Monday, October 29, 2018 at 9:33 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Post retirement doctors establishing new career heights – Story Consideration
Dear Aviva,
Would you be interested in interviewing personalities in the medical Fraternity?
Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.
Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education.
I have attached the award letter to this email for your information.
Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.
Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.
Best regards,
Daphne
Executive
Corporate Communications
DID (65) 6705 2769
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Friday, June 1, 2018 at 3:26 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>
Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again
Dear Dr. Lev-Ari,
Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.
I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.
Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!
Best,
Nathan
PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.
From: “Prof. Michael Watts” <mwatts@berkeley.edu>
Date: Sunday, May 13, 2018 at 1:29 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University
Dear Aviva: a very long time! Nice to hear from you and your later extraordinary career! And it seems like you are now on Phase IV. Very exciting.
I am retiring in June but will of course keep writing and conducting research.
You may have heard that Allan’s wife Hjordis passed away relatively recently. It was nice to see their children again at the memorial.
Warmly, Michael
On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:
See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down
If interested to read more, click on:
Aviva’s books on AMAZON.COM
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Dear Professors, Watts, Walker, Sayre, Laguerr and Segev,
I hope you are well and will enjoy the months of Summer coming up.
We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.
I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.
It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.
I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Please Read these two:
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
I attended the 1998 – 100 years Geography Department celebration.
Please review the following, it can be included in the future Itinerant Geographer.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Thank you – Good Luck to you
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Thursday, March 8, 2018 at 6:07 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago
Dear Aviva,
Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.
You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.
Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.
It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:
Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.
Best,
Nathan
On Monday, July 24, 2017 at 9:27 PM
From: marzan Khan <marzan.khan@mail.mcgill.ca>
Date: Monday, July 24, 2017 at 9:27 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2
Hello Aviva,
Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.
Best of luck on the e-book and all your endeavors.
Sincerely,
Marzan Khan
On June 18, 2017, 9;39AM
Dear Aviva Lev-Ari,
Thank you very much for your email.
First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.
I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.
Sincerely from Beijing
Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg
On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:
Hi Aviva,
Thanks! I am also excited to join Regeneron.
Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.
Best
Anamika Sarkar, PhD
@@@@@@
From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>
Date: Wednesday, April 27, 2016 at 11:32 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Thanks Aviva.
You obviously work hard on this!
Keep up the hard work.
Mark
MARK COBBOLD, MD, PHD
From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
LinkedIn Profile Twitter Profile
@@@@@
From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>
Date: Friday, March 18, 2016 at 11:46 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>
Subject: RE: REVOTEK follow up for 3D printing – AVIVA
Hello Aviva:
To answer your questions:
The ownership at regenHU is as is.
The CEO of regenHU is Mr. Marc Thurner
The other CPA Group companies are unchanged i.e. no updates
With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.
I truly hope we can work together since I’m impressed with your activities. Have a great weekend.
Regards,
Tony
Tony Arquisch
Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch
CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre
Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch
LinkedIn Profile / XING Profile / Twitter Profile
@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: February 19, 2016 at 3:40:19 PM EST
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>
Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Dr. Lev-Ari:
Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision.
By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders.
Have a good weekend.
Very sincerely,
Chris
Christopher J. Wells, M.P.A.
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog: Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@
2/12/2016
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination
| Book Title: * | Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
| Publisher(s): * | Amazon Kindle Direct |
| Publication Date: (Please select one): * | November 2015 |
| Book Entry Summary (Please limit to 100 words): * | The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
@@@@@@@
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
@@@@@@@@@
From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>
Date: Tuesday, January 19, 2016 at 1:09 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence
Wow!!!!! That’s very impressive. So proud of being part of this group and project. Good job everyone.
Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.
Good job everyone!!!
Best
Tilda
@@@@@@@@@
From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>
Date: Sunday, January 10, 2016 at 6:13 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: Re: big data start up for you to talk to…
Dear Aviva,
Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!
Gregory
On 1/9/2016, I wrote to Gregory:
My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:
– Journal, ~4000 articles archived, 900,000 e-Readers
– e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016
– Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.
In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using
- BioMEMS for Gene Editing
- BioMEMS for Tissue Engineering
- BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.
We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.
@@@@@@@@
Please see #3
Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP
16 NOV 5 FOR TODAY
Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share
- Responsible innovation in health care and dual use research. [ Health Kid ]
- A patient’s point of view. [ HRBR ]
- Drivers of Patient Experience. [ LPBI ]
- 5 ways providers can improve the patient experience. [ FierceHealthIT ]
- Telehealth is essential to lowering readmission rates. [ mHealthNews ]
@@@@@@@@
From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Date: Friday, November 13, 2015 at 10:14 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Invitation
|
@@@@@@@@@
From: Anne Sim <georgeclinicalau@gmail.com>
Date: Monday, August 3, 2015 at 3:39 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: contributing
Hello,
I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.
We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.
We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.
Thanks,
Anne Sim
@@@@@@@@@@@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: Wednesday, September 2, 2015 at 11:36 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Thank you for re-blogging our post
Hi Dr. Lev-Ari:
I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful.
I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine.
Thank you again.
Sincerely,
Chris
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog:Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@@@@@@@@@@@
Testimonials about LPBI
2021
UPDATED on 9/29/2021
Tweet
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,
Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.
It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –
Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)
Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO
Any other questions please don’t hesitate to reach out!
All the best,
Charlotte
2020
Updated on 8/25/2020
From: Robin Neff Clebnik <robin@internboston.com>
Date: Tuesday, August 25, 2020 at 5:23 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Thank You!
Hi Aviva,
Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.
By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.
We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.
Best,
Robin
robin neff clebnik
Chief Internship Officer
t: 617.527.0055
m: 617.875.4614
Updated on 8/23/2020
The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:
I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r
the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.
That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.
I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors.
Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources:
- The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
Curator: Aviva Lev-Ari, PhD, RNWith heartfelt gratitude to our Dear Dr. Larry
Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:
- Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series
Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- My Memories Tell a Story to Share
Author: Larry Howard Bernstein, MD, FCAP
Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:
- Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
Updated on 8/11/2020
The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation
The Voice of Internship Team’s Captain, Daniel, Menzin:
LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.
The Voice of Noam Steiner Tomer:
Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!
The Voice of Zach Day:
This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research. In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings. I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari.
Updated on 6/3/2020
Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award
Reporter: Gail S. Thornton, M.A.
Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.
In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology, at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.
###
Updated on 5/7/2020
From: Alan Kaul <alan@mom-inc.us>
Date: Thursday, May 7, 2020 at 9:03 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Vinit Nair <vinit@pracnet.org>
Subject: Pharmaceutical Intelligence
HI Aviva,
You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.
[ see www.mom-inc.us ]
This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.
I hope that this link will prove helpul to both of us
Stay safe,
Alan
Updated on 4/19/2020
ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020
“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”
Sincerely,
Larry Bernstein, MD
“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”
https://lnkd.in/ekWGNqA
In:
My Memories Tell a Story to Share, 4/19/2020
Author: Larry Howard Bernstein, MD, FCAP
Contact: 413-727-8523
Updated on 2/9/2020
Obtained by Gail S. Thornton on 2/7/2020
Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators.
In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field.
I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology.
—Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.
Updated on 1/31/2020
Notifications from ResearchGate
Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Apr 6, 2019
Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Mar 25, 2019
Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 27, 2018
Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 29, 2018
Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jul 27, 2018
Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Oct 10, 2016
Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Jan 9, 2016
Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I
Dec 12, 2015
UPDATED on 1/10/2020
The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
Dr. Marcus Feldman
Professor of Biology, Stanford University
Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”
Dr. Justin Pearlman
Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist
Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications. He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”
Dr. Stephen Williams
Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University
Dr. Williams has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.
It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”
He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”
Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org
She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”
11/27/2019
Dear Aviva,
Thank You note from sandraleebatista@yahoo.com
Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.
We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.
Best wishes,
Sandra
5/29/2019
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 3:13 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Wednesday, May 29, 2019 12:46 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari
Subject: Re: Permission to reprint image
Dear Prof. Klein,
Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.
It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.
See
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions:
A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]
B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication
C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above
Regarding re-publishing the figure:
I am suggesting to add the following comment:
Image Source:
Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP
https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/
I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.
Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.
Please keep in touch and I encourage you to continue to search our Journal archive.
Best regards,
PS
This e-mail is your e-written permission to re-publish figure as commented, above.
Leaders in Pharmaceutical Intelligence portal: http://pharmaceuticalintelligence.com
LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Wednesday, May 29, 2019 at 9:12 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Permission to reprint image
Thank you so much Aviva.
The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.
The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.
Appreciatively,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Sent: Tuesday, May 28, 2019 12:17 PM
To: Klein, Susan Beth
Cc: Stephen Williams, PhD; Marcus W Feldman
Subject: Re: Permission to reprint image
Dear Prof. Klein,
It is always most endearing to correspond with another fellow Alumna of Berkeley.
Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.
Thank you for reaching out to me for permission to reprint a figure.
Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com
Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com
I will then research and grant you re-printing permission in e-writing.
Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:
1.You may find of interest the following e-Books of ours
Series B: Frontiers in Genomics Research
- VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Work-in-Progress
Series C: e-Books on Cancer & Oncology
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
2. My articles on medical OUTCOMES of Radiation Biology on Cardiotoxicity
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Curator: Aviva Lev-Ari, PhD, RN
3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
Reporter: Aviva Lev-Ari, PhD, RN
2019
http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/
My Journal on Cardiotoxicity on Scoop.it
https://www.scoop.it/topic/cardiotoxicity
Looking forward to getting name of article when the figure had appeared in our publications.
Good luck,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
From: “Klein, Susan Beth” <sbklein@indiana.edu>
Date: Tuesday, May 28, 2019 at 11:11 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Permission to reprint image
Hello Aviva Lev-Ari,
I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!
Regards,
Susan
Susan B. Klein, PhD
Department of Physics
Swain West 331
Indiana University, Bloomington
812.855.9687
(another Berkeley alum)
April 2019
2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19
via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
4/21/2019
From: Amnon Danzig <amnon.danzig@gmail.com>
Date: Sunday, April 21, 2019 at 4:17 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: A Letter from Amnon Danzig
Dear Aviva
Now, I read the two docs in depth.
Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…
It is my honor to work with you and the team.
I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.
I would like to thank you for your very fine and warm words about my contribution. GREAT!
I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.
Why?
My thinking was always going to the ways to present LPBI Group the best it can.
I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.
Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.
I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!
Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.
If you happen to have ideas for me, great.
This is the reason I extend my time in NYC.
BR
Amnon
@@@@@
4/19/2019
LPBI Group: The Business Opportunity
Voice of Prof. Marcus W. Feldman
The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.
@@@@@
4/19/2019
LPBI Group: The Business Plan
Voice of Aviva Lev-Ari, Founder
The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).
- The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD).
- The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
- They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
- Further development of this Business Plan document will follow in the near future.
This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.
This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.
@@@@@
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
@@@@
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI@PHSInnovation @ChrisMarkCOBURN http://bit.ly/WMIF19
@@@@
Top influencer 3rd place @AVIVA1950
This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.
https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125
@@@@
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, April 10, 2019 at 10:16 PM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>
Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph
Well done! 3rd place for #WMIF19 is good
See
Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
@@@@
From: Leny <gochevav@mit.edu>
Date: Wednesday, November 28, 2018 at 11:30 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN
Dear Dr. Lev-Ari,
I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.
To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets -> select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.
Please do not hesitate to reach out if you have any additional questions.
Best,
Leny
Vasilena Gocheva, PhD | Assistant Director | MIT Center for Precision Cancer Medicine | 77 Massachusetts Avenue, 76-353 | Cambridge, MA 02139 | cpcm.mit.edu
From: Shankar Khatkale <shankar.k@gminsights.com>
Date: Tuesday, November 27, 2018 at 6:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Article Submission Request
Dear Editor,
An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.
News Link: https://www.gminsights.com/pressrelease/precision-medicine-market
Looking forward to hear from you.
On behalf of and as instructed by Global Market Insights, Inc.
Best Regards,
Shankar Khatkale |SEO Executive
From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>
Date: Monday, October 29, 2018 at 9:33 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Post retirement doctors establishing new career heights – Story Consideration
Dear Aviva,
Would you be interested in interviewing personalities in the medical Fraternity?
Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.
Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education.
I have attached the award letter to this email for your information.
Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.
Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.
Best regards,
Daphne
Executive
Corporate Communications
DID (65) 6705 2769
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Friday, June 1, 2018 at 3:26 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>
Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again
Dear Dr. Lev-Ari,
Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.
I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.
Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!
Best,
Nathan
PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.
From: “Prof. Michael Watts” <mwatts@berkeley.edu>
Date: Sunday, May 13, 2018 at 1:29 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University
Dear Aviva: a very long time! Nice to hear from you and your later extraordinary career! And it seems like you are now on Phase IV. Very exciting.
I am retiring in June but will of course keep writing and conducting research.
You may have heard that Allan’s wife Hjordis passed away relatively recently. It was nice to see their children again at the memorial.
Warmly, Michael
On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:
See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down
If interested to read more, click on:
Aviva’s books on AMAZON.COM
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
Dear Professors, Watts, Walker, Sayre, Laguerr and Segev,
I hope you are well and will enjoy the months of Summer coming up.
We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.
I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.
It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.
I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
Please Read these two:
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
I attended the 1998 – 100 years Geography Department celebration.
Please review the following, it can be included in the future Itinerant Geographer.
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Thank you – Good Luck to you
From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>
Date: Thursday, March 8, 2018 at 6:07 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago
Dear Aviva,
Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.
You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.
Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.
It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:
Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.
Best,
Nathan
On Monday, July 24, 2017 at 9:27 PM
From: marzan Khan <marzan.khan@mail.mcgill.ca>
Date: Monday, July 24, 2017 at 9:27 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2
Hello Aviva,
Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.
Best of luck on the e-book and all your endeavors.
Sincerely,
Marzan Khan
On June 18, 2017, 9;39AM
Dear Aviva Lev-Ari,
Thank you very much for your email.
First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.
I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.
Sincerely from Beijing
Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg
On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:
Hi Aviva,
Thanks! I am also excited to join Regeneron.
Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.
Best
Anamika Sarkar, PhD
@@@@@@
From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>
Date: Wednesday, April 27, 2016 at 11:32 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Thanks Aviva.
You obviously work hard on this!
Keep up the hard work.
Mark
MARK COBBOLD, MD, PHD
From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE 8:00 am 12:00 pm 4/25/2016 First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
LinkedIn Profile Twitter Profile
@@@@@
From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>
Date: Friday, March 18, 2016 at 11:46 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>
Subject: RE: REVOTEK follow up for 3D printing – AVIVA
Hello Aviva:
To answer your questions:
The ownership at regenHU is as is.
The CEO of regenHU is Mr. Marc Thurner
The other CPA Group companies are unchanged i.e. no updates
With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.
I truly hope we can work together since I’m impressed with your activities. Have a great weekend.
Regards,
Tony
Tony Arquisch
Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch
CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre
Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch
LinkedIn Profile / XING Profile / Twitter Profile
@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: February 19, 2016 at 3:40:19 PM EST
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>
Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Dr. Lev-Ari:
Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision.
By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders.
Have a good weekend.
Very sincerely,
Chris
Christopher J. Wells, M.P.A.
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog: Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@
2/12/2016
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination
| Book Title: * | Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
| Publisher(s): * | Amazon Kindle Direct |
| Publication Date: (Please select one): * | November 2015 |
| Book Entry Summary (Please limit to 100 words): * | The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
@@@@@@@
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
@@@@@@@@@
From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>
Date: Tuesday, January 19, 2016 at 1:09 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence
Wow!!!!! That’s very impressive. So proud of being part of this group and project. Good job everyone.
Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.
Good job everyone!!!
Best
Tilda
@@@@@@@@@
From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>
Date: Sunday, January 10, 2016 at 6:13 AM
To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>
Subject: Re: big data start up for you to talk to…
Dear Aviva,
Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!
Gregory
On 1/9/2016, I wrote to Gregory:
My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:
– Journal, ~4000 articles archived, 900,000 e-Readers
– e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016
– Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.
In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using
- BioMEMS for Gene Editing
- BioMEMS for Tissue Engineering
- BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.
We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.
@@@@@@@@
Please see #3
Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP
16 NOV 5 FOR TODAY
Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share
- Responsible innovation in health care and dual use research. [ Health Kid ]
- A patient’s point of view. [ HRBR ]
- Drivers of Patient Experience. [ LPBI ]
- 5 ways providers can improve the patient experience. [ FierceHealthIT ]
- Telehealth is essential to lowering readmission rates. [ mHealthNews ]
@@@@@@@@
From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>
Date: Friday, November 13, 2015 at 10:14 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Invitation
|
@@@@@@@@@
From: Anne Sim <georgeclinicalau@gmail.com>
Date: Monday, August 3, 2015 at 3:39 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: contributing
Hello,
I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.
We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.
We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.
Thanks,
Anne Sim
@@@@@@@@@@@@@@@@@
From: Christopher Wells <cwells@personalizedmedicinecoalition.org>
Date: Wednesday, September 2, 2015 at 11:36 AM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Thank you for re-blogging our post
Hi Dr. Lev-Ari:
I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful.
I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine.
Thank you again.
Sincerely,
Chris
Communications Director
Cwells@personalizedmedicinecoalition.org
Direct: 202-589-1755 I Mobile: 202-580-9780
Personalized Medicine Coalition
Blog:Education & Advocacy
Twitter: @PerMedCoalition
1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036
www.PersonalizedMedicineCoalition.org
@@@@@@@@@@@@@@@@@
Testimonials about LPBI
2021
UPDATED on 9/29/2021
Tweet
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum
liked your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice
Retweeted your Tweet
@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be
UPDATED on 9/22/2021
From INTERNS in 2021 LPBI’s Summer Internship
From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Hi Aviva,
This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.
The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.
Looking forward to staying in touch,
Ethan
UPDATED on 6/1/2021 for May 24, 2021
From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors
Notable Tweets
@mandywoodland
@LeapsByBayer
@DrLilitGaribyan
@MPDexpert
@AVIVA1950 is Aviva Lev-Ari, PhD, RN
UPDATED on 2/15/2021
From: Nigel Russell <nrussell@jofpm.com>
Date: Monday, February 15, 2021 at 10:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: About our Venture
Dear Dr. Lev-Ari:
Thank you for the information and outreach. You have a very interesting platform.
I am interested in chatting.
Kind regards,
Nigel
Nigel Russell
President
The Journal of Precision Medicine & the Precision Medicine Leaders Summit
Updated on 1/6/2021
From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>
Date: Tuesday, January 5, 2021 at 10:47 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RE: REUTERS NEXT Press Registration Deadline this Friday (Jan 8)
Hi Aviva,